How to Get Dayvigo (Lemborexant) in Louisiana

What Is Dayvigo and How Does It Work?

Dayvigo is a dual orexin receptor antagonist (DORA) that blocks both OX1R and OX2R receptors, reducing the wake-promoting signals that orexin neuropeptides send to the brain. The result is a reduction in sleep-onset latency and wake time after sleep onset without fully suppressing normal sleep architecture. Unlike benzodiazepines, lemborexant does not bind GABA-A receptors, which means it carries a lower risk of respiratory depression and a distinct side-effect profile.

The FDA approved lemborexant in December 2019 based on the SUNRISE-1 and SUNRISE-2 trials. SUNRISE-1 (N=291) demonstrated that lemborexant 5 mg and 10 mg both produced statistically significant reductions in subjective sleep-onset latency compared to placebo and to zolpidem ER 6.25 mg over 30 days of treatment [1]. The 10 mg dose reduced subjective sleep-onset latency by a mean of 22 minutes from baseline versus 9.4 minutes for zolpidem ER and 6.4 minutes for placebo [1]. Those are not small differences in a population where 20 extra minutes of faster sleep onset changes daily function.

SUNRISE-2 extended the observation window to 12 months across 949 participants and showed sustained efficacy without evidence of tolerance development [2]. The FDA label specifies that the maximum recommended dose is 10 mg once nightly, and the prescriber should use the lowest effective dose [3].

Dayvigo is classified as a Schedule IV controlled substance under the DEA Controlled Substances Act, placing it in the same category as zolpidem and eszopiclone but below the stricter Schedule III and IV restrictions that apply to benzodiazepines in certain state formularies [4].

Who Can Prescribe Dayvigo in Louisiana?

Any licensed prescriber with DEA Schedule IV authority can write a Dayvigo prescription in Louisiana. That includes physicians (MD, DO), nurse practitioners (APRN) with prescriptive authority, and physician assistants (PA) operating under a written practice agreement. Louisiana Board of Pharmacy rules do not restrict Dayvigo to any specialty, so a primary care provider, psychiatrist, or sleep medicine specialist can all prescribe it.

Louisiana APRNs hold independent prescriptive authority for Schedule IV controlled substances under Louisiana Revised Statute 37:913, provided they maintain their own DEA registration [5]. PAs in Louisiana prescribe Schedule IV medications under a written collaborative practice agreement with a supervising physician. Both pathways are valid for Dayvigo.

Sleep medicine fellowship training is not required. A clinician who takes an adequate sleep history, screens for contraindications (including severe hepatic impairment, which is a labeled contraindication), and documents a chronic insomnia diagnosis under DSM-5 criteria can legally initiate lemborexant.

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guidelines for Pharmacologic Treatment of Chronic Insomnia in Adults stated: "We suggest that clinicians use lemborexant (suvorexant class) rather than no treatment for sleep maintenance insomnia" [6]. That guideline recommendation was based on moderate-quality evidence at the time of publication and has not been downgraded in subsequent updates.

Can You Get Dayvigo Through Telehealth in Louisiana?

Yes. Louisiana permits synchronous audio-video telehealth prescribing of Schedule IV controlled substances for established and new patients, subject to federal Ryan Haight Act requirements. The DEA's telemedicine special registration framework, extended through 2025, allows prescribing of Schedule III and IV substances via telehealth when the clinician conducts a real-time, two-way audio-video consultation and documents a valid prescriber-patient relationship [7].

Practical requirements for a Louisiana telehealth Dayvigo consultation include:

1. A live audio-video platform (not phone-only) that meets HIPAA technical standards.
2. A complete sleep history covering duration, onset, sleep hygiene, prior medication trials, and daytime impairment consistent with chronic insomnia (symptoms at least 3 nights per week for at least 3 months per DSM-5) [8].
3. A medication reconciliation to identify interactions, particularly CNS depressants. Concomitant use of strong CYP3A4 inhibitors such as clarithromycin is contraindicated per the FDA label because lemborexant is primarily metabolized via CYP3A4 [3].
4. A state-valid photo ID and a Louisiana billing address.

HealthRX connects Louisiana residents with licensed clinicians who hold Louisiana medical licenses and active DEA registrations. A typical intake-to-prescription timeline runs 48 to 72 hours from completed intake forms to a sent prescription.

What Labs Are Needed Before Starting Dayvigo?

No routine laboratory panel is mandated by the FDA label or by the AASM chronic insomnia guidelines before initiating lemborexant in otherwise healthy adults. The label flags one absolute contraindication requiring clinical assessment: severe hepatic impairment (Child-Pugh C), because lemborexant's mean AUC increases approximately 4-fold in severe hepatic impairment compared to healthy subjects [3].

Clinicians may order specific tests based on individual clinical judgment:

• Liver function tests (LFTs): Ordered selectively if the patient has known liver disease, heavy alcohol use, or takes hepatotoxic medications. Not a universal requirement.
• Polysomnography (PSG): The AASM guideline does not require PSG before pharmacotherapy for chronic insomnia in the absence of clinical suspicion for obstructive sleep apnea or periodic limb movement disorder [6].
• Epworth Sleepiness Scale (ESS): Used at many practices as a baseline to track treatment response. The ESS is a validated 8-item self-report questionnaire; a score above 10 suggests excessive daytime sleepiness [9].
• Urine drug screen: Ordered at prescriber discretion, particularly when co-prescribing other controlled substances.

A full metabolic panel is typically not required for a healthy adult starting 5 mg lemborexant. If your provider orders one, it is most likely driven by clinical history rather than a lemborexant-specific protocol.

How to Get a Dayvigo Prescription in Louisiana: Step-by-Step

Getting Dayvigo in Louisiana follows a straightforward sequence regardless of whether you see a clinician in person or via telehealth.

Step 1. Document your insomnia history. Gather information on how long sleep problems have persisted (must be at least 3 months for a chronic insomnia diagnosis), how often per week, whether the problem is sleep-onset, sleep-maintenance, or both, and what non-pharmacologic approaches you have tried. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment per AASM guidelines, and many insurers require documentation of a CBT-I trial before approving a prescription [6].

Step 2. Book a consultation. Schedule with a Louisiana-licensed clinician. Telehealth is legally available for Schedule IV prescribing in Louisiana. The visit should be synchronous audio-video, not asynchronous messaging.

Step 3. Complete the clinical evaluation. Expect questions about sleep hygiene, alcohol and caffeine use, prior sleep medications, current medications (particularly CYP3A4 inhibitors), and any history of parasomnias. Lemborexant carries a class warning about complex sleep behaviors; inform your prescriber about any history of sleepwalking or sleep-driving [3].

Step 4. Receive and transmit the prescription. Louisiana pharmacies accept electronic prescriptions for Schedule IV controlled substances. The prescriber sends the Rx electronically to your chosen pharmacy.

Step 5. Fill the prescription and confirm cost. Eisai offers a co-pay savings card for commercially insured patients that may reduce out-of-pocket costs significantly. Louisiana Medicaid does not cover Dayvigo, so Medicaid recipients should ask about the savings program or explore GoodRx pricing, which ranges from approximately $280 to $340 for 30 tablets at most Louisiana retail chains.

Insurance Coverage and Prior Authorization in Louisiana

Louisiana Medicaid (Healthy Louisiana) does not include lemborexant on its preferred drug list. Commercial insurers in Louisiana vary widely. UnitedHealthcare, Cigna, and Blue Cross Blue Shield of Louisiana all list Dayvigo as a non-preferred specialty or brand drug requiring prior authorization (PA) on many formularies.

A prior authorization for Dayvigo in Louisiana typically requires:

• A DSM-5 or ICD-10 diagnosis of insomnia disorder (F51.01 for insomnia disorder, not otherwise specified; G47.00 for insomnia unspecified).
• Documentation of an adequate trial of at least one preferred generic sleep agent, usually zolpidem or eszopiclone, of sufficient duration (typically 4 weeks or more) with documented inadequate response, side effects, or contraindication.
• Documentation that CBT-I was offered, attempted, or is not locally available.
• A prescriber attestation that the patient has chronic insomnia (symptoms 3 or more nights per week for 3 or more months).

The American College of Physicians (ACP) recommends CBT-I as the initial treatment for adult chronic insomnia disorder and positions pharmacologic therapy as a second step when CBT-I is not sufficiently effective [10]. Having that sequencing documented in the chart strengthens a prior authorization appeal if the initial request is denied.

Most Louisiana commercial plans process prior authorization requests within 3 business days for non-urgent requests. Urgent requests (when a prescriber certifies medical necessity for faster review) are processed within 24 to 72 hours under Louisiana Department of Insurance regulations.

Dayvigo Pharmacy Access in Louisiana

Retail and mail-order pharmacies across Louisiana can dispense lemborexant. Major chains including CVS, Walgreens, Rite Aid, and Walmart Pharmacy carry or can order lemborexant 5 mg and 10 mg tablets. Independent Louisiana pharmacies may need 24 to 48 hours to stock an initial fill.

503A compounding pharmacies: Louisiana-licensed 503A compounding pharmacies may prepare lemborexant formulations for patients with documented medical necessity for an alternative dose form. For example, a patient unable to swallow tablets might receive a compounded oral solution. The FDA regulates 503A compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act; the compounding must be for an individual patient with a valid prescription [11]. Louisiana Board of Pharmacy Rule LAC 46:LIII.2703 governs 503A compounding operations in the state and requires pharmacies to be licensed with the Louisiana Board of Pharmacy.

Mail-order pharmacy: Telehealth patients often prefer mail-order for convenience. Louisiana law permits mail-order dispensing of Schedule IV controlled substances provided the prescription is electronically transmitted and the dispensing pharmacy holds an active Louisiana non-resident pharmacy permit. Typical delivery is 3 to 5 business days via standard shipping or 1 to 2 days via expedited shipping.

Transfer of an existing Dayvigo prescription to Louisiana: Transferring a Schedule IV prescription from another state to a Louisiana pharmacy is permitted once per fill. The receiving Louisiana pharmacist contacts the original pharmacy, verifies remaining refills, and creates a new record. Federal law limits Schedule IV prescriptions to a maximum of 5 refills within 6 months of the original issue date [4].

Dosing, Titration, and Safety Information

The FDA-approved starting dose for most adults is lemborexant 5 mg taken immediately before bed, with at least 7 hours remaining before the planned wake time [3]. If 5 mg is tolerated but not sufficiently effective after 1 to 2 weeks, the prescriber may increase to 10 mg. The 10 mg dose should not be exceeded.

Older adults (age 65 and above) may be more sensitive to next-morning psychomotor impairment. The SUNRISE-1 trial found that lemborexant 10 mg increased next-day driving impairment on standardized road tests compared to placebo and to zolpidem ER 6.25 mg in participants age 55 and above [1]. The FDA label specifically states that the 5 mg dose is recommended for elderly patients because of this finding.

Key drug interactions to discuss with your Louisiana prescriber:

• Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir): Contraindicated. Lemborexant exposure increases substantially [3].
• Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem): Use with caution; consider reducing lemborexant to 5 mg [3].
• CNS depressants (alcohol, opioids, benzodiazepines): Additive sedation. Avoid concurrent use or counsel carefully if co-prescribed [3].
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): May reduce lemborexant efficacy significantly; avoid co-administration [3].

Lemborexant is rated FDA Pregnancy Category not yet reassigned under the 2015 labeling rule system; the label indicates that animal studies showed developmental toxicity at doses producing plasma exposures greater than the maximum recommended human dose, and the drug should be used during pregnancy only if the potential benefit justifies the potential risk [3].

Next-Morning Impairment and Driving in Louisiana

Louisiana law prohibits driving while impaired by any substance, including legally prescribed sleep medications. The FDA label for lemborexant includes a warning that next-morning psychomotor impairment is possible, particularly at the 10 mg dose. A 2020 study in Clinical Pharmacology and Therapeutics (N=60) measured simulated and on-road driving performance at 9 hours post-dose and found that lemborexant 10 mg produced statistically significant lane-keeping impairment compared to placebo at the 9-hour mark, while the 5 mg dose did not reach statistical significance [12].

Patients should not drive or operate heavy machinery until they know how lemborexant affects them individually. Louisiana does not have a specific per-se legal limit for lemborexant blood concentration (unlike alcohol), so impairment is assessed behaviorally by law enforcement.

What to Expect at Your First Dayvigo Fill

At the pharmacy counter or upon mail-order receipt, patients should expect a mandatory counseling offer under federal OBRA-90 requirements. The pharmacist or pharmacy technician will offer to explain dosing, storage (store at controlled room temperature, 68 to 77 degrees Fahrenheit), and the medication guide that Eisai is required to distribute with each fill.

Lemborexant tablets should be taken whole. They should not be crushed or chewed; no published data support modified-release pharmacokinetics when the tablet is altered, and the FDA label does not address this scenario [3]. Take the tablet immediately before bed, not during the night if you wake up.

If sleep onset or maintenance does not improve after 4 weeks at 10 mg, the prescriber should reassess the diagnosis, consider referral for PSG to rule out untreated sleep apnea, and evaluate whether CBT-I has been adequately tried. The AASM notes that pharmacotherapy response should be evaluated at 4-week intervals with a validated instrument such as the Insomnia Severity Index (ISI) [6].

The Insomnia Severity Index is a 7-item self-report measure with a maximum score of 28. A score of 8 to 14 indicates subthreshold insomnia, 15 to 21 moderate insomnia, and 22 to 28 severe insomnia. Clinicians in Louisiana using HealthRX track ISI scores at baseline, 4 weeks, and 12 weeks to assess treatment response objectively.